ISRCTN15192099已完成未知
Survival of patients with recurrent glioblastoma multiforme treated with local carmustine wafer (Gliadel® ) in relation to the methylation of methylguanin-DNA-methyltransferase (MGMT) promotor
nfallkrankenhaus Berlin0 个研究点目标入组 60 人开始时间: 2016年4月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. First recurrent manifestation of a glioblastoma multiforme
- •2. Female and male =18 years
- •3. Previous adjuvant radio-chemotherapy chemotherapy in accordance with the ”Stupp protocol
- •4. The indication for revision surgery follows the usual balancing of risks and benefits of the therapy, informed consent and –finally- decision of the patient
排除标准
- •1. Patients who underwent more than one surgical revision of malignant glioma
- •2. Previous implantation of carmustine wafer (Giadel ®)
- •3. More than six cycles of the Stupp scheme (radio-chemotherapy)
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate the potentiation effect of radiotherapy by AGuIX nanoparticles for the treatment of persistent glioblastomaPersistent Glioblastoma Multiforme, grade IVMedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003774-32-ITDIPARTIMENTO BIOMEDICINA E PREVENZIONE UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA30
已完成
不适用
Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSSGlioblastoma MultiformeNCT04810182Istituto Oncologico Veneto IRCCS192
撤回
不适用
Role of Repeat Resection in Recurrent GlioblastomaGlioblastoma - CategoryRecurrent GlioblastomaNCT04838782University of Alberta250
已完成
2 期
Regorafenib in Relapsed GlioblastomaGlioblastoma MultiformeNCT02926222Istituto Oncologico Veneto IRCCS119
招募中
3 期
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III StudyFirst Progression of GlioblastomaNCT05904119European Organisation for Research and Treatment of Cancer - EORTC411